Gedea Biotech initiates EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Up to 75% of all women are affected by vaginal infection in their lifes Self-diagnoses leads often to unnecessary and inappropriate treatment use This study aims to confirm the safety and efficacy of pHyph in VVC Lund, Sweden, May 2, 2023. Gedea Biotech today announces that the treatment of the…
Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis
Important expansion of patent estate in the largest market for vaginal bacterial infections pHyph has shown superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Lund, Sweden, April 18, 2023. Swedish women’s health company Gedea Biotech announced…
Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification
Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the approved certification are important milestones for achieving CE marking for pHyph, the…
Gedea Biotech awarded SEK 3M from SWElife and MedTech4Health for groundbreaking antibiotic free women’s health trial
Impact on microbiome could be key to preventing vulvovaginal infection recurrence Lund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge…
Two mentions and one article in three publications during end of November
News The results from the NEFERTITI-study have received much attention since they were first published in a press release from October 11th. During the last week of November, there were no less than three publications that mentioned Gedea and were spread through e.g., Twitter and LinkedIn. First…
Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
Uppdated 2022-11-14 - Symptom reduction was seen in 90% of patients and absence of symptoms was noted in 70% of patients - Clinical cure rate was 50,4% in the pHyph group, which is in line with many antibiotic treatments on the market - The rate of recurrence of BV was substantially lower at day 35…
Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
PRESS RELEASE Gedea Biotech today announces that it has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal tablet for topical treatment. The open-labelled study is designed to…
Gedea Biotech wins the "Rapidus company of the year" award
PRESS RELEASE
Gedea Biotech has been awarded the prestigious award "Rapidus Company of the Year". The ceremony…
Gedea Biotech has completed the recruitment for NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
PRESS RELEASE Lund, Sweden, February 08, 2022. Swedish women’s health company Gedea Biotech today announced that despite the COVID-19 pandemic it has successfully completed recruitment of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of…
Gedea Biotech - Top 20 European Biotech Companies to Watch in 2022
Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list "The 20 European Biotech Companies to Watch in 2022". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a…